sounds like you are in the wrong investment. clinical trial results and timeframes are pretty open and updated by the company as with enrolment take up. financial management is fantastic and the boards salary is comparably on the small side. managements incentives are aligned to yours.
Zelda keeps quiet your right. we don't spend much on marketing and hype. it's heads down and quiet focusing on clinical outcomes. we need a data asset and it's just around the corner. pivotal.
Ann: Zelda to merge with US-based Ilera Therapeutics, page-289
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ZLD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.077M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1457 | 71.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 76.5¢ | 64 | 2 |
View Market Depth
| Last trade - 16.12pm 16/08/2024 (20 minute delay) ? |
| ZLD (ASX) Chart |
Day chart unavailable